
Garrett Michael Nash MD MPH
Surgeon, Memorial Sloan Kettering Associate Professor, Surgery, Weill Cornell Medical College
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Nash
Garrett M. Nash, MD, MPH, FACS, FASCRS, FSSO is an Attending Surgeon and Vice President, Quality and Safety at the Memorial Sloan Kettering Cancer Center. He oversees the Division of Quality and Safety, and his administrative focus is on using data analysis and reporting to drive process improvements, teaching and training, and nurturing a culture of safety and transparency. He prioritizes efforts to increase the reporting of patient safety events across the organization. He is board-certified in surgery and colorectal surgery. His practice includes robotic surgery for colorectal cancer and regional therapy for colorectal and peritoneal cancers including appendix cancer and mesothelioma. He is the primary investigator of ICARuS and ICARuS II (Intraperitoneal Chemotherapy After Cytoreductive Surgery), randomized clinical trials studying the effectiveness of intraperitoneal therapy for colon and appendix cancer and for peritoneal mesothelioma, respectively. He has authored papers on a variety of subjects including cytoreductive surgery, intraperitoneal chemotherapy, minimally invasive surgery, sphincter-sparing rectal surgery, mechanisms of tumor progression, and predictors of outcome following surgery.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2007 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Colon and Rectal Surgery, 2006 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2003 - 2006
UMass Chan Medical SchoolResidency, Surgery, 1998 - 2000
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2023 - 2027
NY State Medical License 2003 - 2026
American Board of Colon and Rectal Surgery Colon & Rectal Surgery
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FASCRS) American Society of Colon and Rectal Surgeons
- Fellow (FSSO) Society of Surgical Oncology
- America's Top Doctors Castle Connolly, 2016-2020
Clinical Trials
- ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
- A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Start of enrollment: 2023 Sep 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- ASO Visual Abstract: Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.Tina Gowda, Nicole Aguirre, Mostafa Mohamed, Despoina Kanata, Mohammed Ali Abbass
Annals of Surgical Oncology. 2026-03-02 - Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.Tina Gowda, Nicole Aguirre, Mostafa Mohamed, Despoina Kanata, Mohammed Ali Abbass
Annals of Surgical Oncology. 2026-02-20 - Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma.Prashasti Agrawal, Fady Baky, Judy Sarungbam, Joel Sheinfeld, Victor E Reuter
Annals of Surgical Oncology. 2025-12-01
Journal Articles
- Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal DepositsJinru Shia, Garrett M Nash, Philip B Paty, Andrea Cercek, Campbell S Roxburgh, Annals of Surgical Oncology
- Effect of Neoadjuvant Systemic Chemotherapy with or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated with Total Mesorectal ExcisionEmmanouil P Pappou, Garrett M Nash, Jose G Guillem, Martin R Weiser, Philip B Paty, Journal of gastrointestinal surgery
- Effectiveness of a Multidisciplinary Patient Care Bundle for Reducing Surgical‐Site InfectionsG M Nash, P B Paty, J G Guillem, J J Smith, British Journal of Surgery
Press Mentions
ICARuS Post-Operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum with Isolated Peritoneal Metastasis (ICARuS)March 21st, 2013
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPOGreat West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









